Ahmed O. Kaseb, MD, discusses the significance of results from the phase 3 IMbrave050 trial of adjuvant atezolizumab and bevacizumab for patients with early-stage hepatocellular carcinoma.
Ahmed O. Kaseb, MD
Advertisement
Articles by Ahmed O. Kaseb, MD
Ahmed O. Kaseb, MD, discusses the safety profile of the combination of atezolizumab and bevacizumab in hepatocellular carcinoma.
Ahmed O. Kaseb, MD, a professor in the Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, discusses research with targeted therapy in hepatocellular carcinoma (HCC).
Ahmed O. Kaseb, MD, discusses the progression of therapy options for patients with hepatocellular carcinoma.
Advertisement
Latest Updated Articles
Dr. Kaseb on the Progression of HCC ResearchPublished: March 12th 2020 | Updated:
Dr. Kaseb on Research With Targeted Therapy in HCCPublished: April 2nd 2020 | Updated:
Dr. Kaseb on Safety Profile of Atezolizumab Plus Bevacizumab in HCCPublished: April 22nd 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Priority Review to Gedatolisib for HR+, HER2-Negative Advanced Breast Cancer
2
Legubicin More Than Doubles PFS in Advanced Soft Tissue Sarcoma
3
Unpacking the FDA Approvals That Reshaped Cancer Care in 2025
4
NCCN Guidelines Recognize MammaPrint/BluePrint for Determining Anthracycline Benefit in Breast Cancer
5